About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Psoriasis Drug Market Size, Share & Growth Analysis 2032
Psoriasis Drug Market

Psoriasis Drug Market Size, Share & Trends Analysis Report By Drug Class (Biologics, Corticosteroids, Vitamin D Analogs, Others), By Therapeutic Class (Tumour Necrosis Factor (TNF), Phosphodiesterase Type 4 (PDE4), Interleukin, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Chanel (Hospital Pharmacies, Retail Pharmacies, E-commerce, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI514DR
Last Updated : February 26, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Psoriasis Drug Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Biologics
        1. By Value
      3. Corticosteroids
        1. By Value
      4. Vitamin D Analogs
        1. By Value
      5. Others
        1. By Value
    3. By Therapeutic Class
      1. Introduction
        1. Therapeutic Class By Value
      2. Tumour Necrosis Factor (TNF)
        1. By Value
      3. Phosphodiesterase Type 4 (PDE4)
        1. By Value
      4. Interleukin
        1. By Value
      5. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
      4. Topical
        1. By Value
    5. By Distribution Chanel
      1. Introduction
        1. Distribution Chanel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. E-commerce
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Biologics
        1. By Value
      3. Corticosteroids
        1. By Value
      4. Vitamin D Analogs
        1. By Value
      5. Others
        1. By Value
    3. By Therapeutic Class
      1. Introduction
        1. Therapeutic Class By Value
      2. Tumour Necrosis Factor (TNF)
        1. By Value
      3. Phosphodiesterase Type 4 (PDE4)
        1. By Value
      4. Interleukin
        1. By Value
      5. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
      4. Topical
        1. By Value
    5. By Distribution Chanel
      1. Introduction
        1. Distribution Chanel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. E-commerce
        1. By Value
      5. Others
        1. By Value
    6. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Biologics
          1. By Value
        3. Corticosteroids
          1. By Value
        4. Vitamin D Analogs
          1. By Value
        5. Others
          1. By Value
      2. By Therapeutic Class
        1. Introduction
          1. Therapeutic Class By Value
        2. Tumour Necrosis Factor (TNF)
          1. By Value
        3. Phosphodiesterase Type 4 (PDE4)
          1. By Value
        4. Interleukin
          1. By Value
        5. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
        4. Topical
          1. By Value
      4. By Distribution Chanel
        1. Introduction
          1. Distribution Chanel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. E-commerce
          1. By Value
        5. Others
          1. By Value
    7. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Biologics
        1. By Value
      3. Corticosteroids
        1. By Value
      4. Vitamin D Analogs
        1. By Value
      5. Others
        1. By Value
    3. By Therapeutic Class
      1. Introduction
        1. Therapeutic Class By Value
      2. Tumour Necrosis Factor (TNF)
        1. By Value
      3. Phosphodiesterase Type 4 (PDE4)
        1. By Value
      4. Interleukin
        1. By Value
      5. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
      4. Topical
        1. By Value
    5. By Distribution Chanel
      1. Introduction
        1. Distribution Chanel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. E-commerce
        1. By Value
      5. Others
        1. By Value
    6. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Biologics
          1. By Value
        3. Corticosteroids
          1. By Value
        4. Vitamin D Analogs
          1. By Value
        5. Others
          1. By Value
      2. By Therapeutic Class
        1. Introduction
          1. Therapeutic Class By Value
        2. Tumour Necrosis Factor (TNF)
          1. By Value
        3. Phosphodiesterase Type 4 (PDE4)
          1. By Value
        4. Interleukin
          1. By Value
        5. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
        4. Topical
          1. By Value
      4. By Distribution Chanel
        1. Introduction
          1. Distribution Chanel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. E-commerce
          1. By Value
        5. Others
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Biologics
        1. By Value
      3. Corticosteroids
        1. By Value
      4. Vitamin D Analogs
        1. By Value
      5. Others
        1. By Value
    3. By Therapeutic Class
      1. Introduction
        1. Therapeutic Class By Value
      2. Tumour Necrosis Factor (TNF)
        1. By Value
      3. Phosphodiesterase Type 4 (PDE4)
        1. By Value
      4. Interleukin
        1. By Value
      5. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
      4. Topical
        1. By Value
    5. By Distribution Chanel
      1. Introduction
        1. Distribution Chanel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. E-commerce
        1. By Value
      5. Others
        1. By Value
    6. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Biologics
          1. By Value
        3. Corticosteroids
          1. By Value
        4. Vitamin D Analogs
          1. By Value
        5. Others
          1. By Value
      2. By Therapeutic Class
        1. Introduction
          1. Therapeutic Class By Value
        2. Tumour Necrosis Factor (TNF)
          1. By Value
        3. Phosphodiesterase Type 4 (PDE4)
          1. By Value
        4. Interleukin
          1. By Value
        5. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
        4. Topical
          1. By Value
      4. By Distribution Chanel
        1. Introduction
          1. Distribution Chanel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. E-commerce
          1. By Value
        5. Others
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Biologics
        1. By Value
      3. Corticosteroids
        1. By Value
      4. Vitamin D Analogs
        1. By Value
      5. Others
        1. By Value
    3. By Therapeutic Class
      1. Introduction
        1. Therapeutic Class By Value
      2. Tumour Necrosis Factor (TNF)
        1. By Value
      3. Phosphodiesterase Type 4 (PDE4)
        1. By Value
      4. Interleukin
        1. By Value
      5. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
      4. Topical
        1. By Value
    5. By Distribution Chanel
      1. Introduction
        1. Distribution Chanel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. E-commerce
        1. By Value
      5. Others
        1. By Value
    6. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Biologics
          1. By Value
        3. Corticosteroids
          1. By Value
        4. Vitamin D Analogs
          1. By Value
        5. Others
          1. By Value
      2. By Therapeutic Class
        1. Introduction
          1. Therapeutic Class By Value
        2. Tumour Necrosis Factor (TNF)
          1. By Value
        3. Phosphodiesterase Type 4 (PDE4)
          1. By Value
        4. Interleukin
          1. By Value
        5. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
        4. Topical
          1. By Value
      4. By Distribution Chanel
        1. Introduction
          1. Distribution Chanel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. E-commerce
          1. By Value
        5. Others
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Biologics
        1. By Value
      3. Corticosteroids
        1. By Value
      4. Vitamin D Analogs
        1. By Value
      5. Others
        1. By Value
    3. By Therapeutic Class
      1. Introduction
        1. Therapeutic Class By Value
      2. Tumour Necrosis Factor (TNF)
        1. By Value
      3. Phosphodiesterase Type 4 (PDE4)
        1. By Value
      4. Interleukin
        1. By Value
      5. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
      4. Topical
        1. By Value
    5. By Distribution Chanel
      1. Introduction
        1. Distribution Chanel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. E-commerce
        1. By Value
      5. Others
        1. By Value
    6. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Biologics
          1. By Value
        3. Corticosteroids
          1. By Value
        4. Vitamin D Analogs
          1. By Value
        5. Others
          1. By Value
      2. By Therapeutic Class
        1. Introduction
          1. Therapeutic Class By Value
        2. Tumour Necrosis Factor (TNF)
          1. By Value
        3. Phosphodiesterase Type 4 (PDE4)
          1. By Value
        4. Interleukin
          1. By Value
        5. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
        4. Topical
          1. By Value
      4. By Distribution Chanel
        1. Introduction
          1. Distribution Chanel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. E-commerce
          1. By Value
        5. Others
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Psoriasis Drug Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Amgen Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Celgene Corporation
    3. AbbVie Inc.
    4. Johnson & Johnson
    5. Novartis, Eli Lilly
    6. AstraZeneca
    7. Pfizer
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Global Osteoporosis Drugs Market Insights The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion in 2025 to USD 19.96 billion by 2033, growing at a CAGR of 3.3% during the foreca
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.